DK3456734T3 - Serinproteasemolekyler og behandlinger - Google Patents

Serinproteasemolekyler og behandlinger Download PDF

Info

Publication number
DK3456734T3
DK3456734T3 DK18202465.3T DK18202465T DK3456734T3 DK 3456734 T3 DK3456734 T3 DK 3456734T3 DK 18202465 T DK18202465 T DK 18202465T DK 3456734 T3 DK3456734 T3 DK 3456734T3
Authority
DK
Denmark
Prior art keywords
treatments
serine protease
protease molecules
molecules
serine
Prior art date
Application number
DK18202465.3T
Other languages
English (en)
Inventor
Michael G Rosenblum
Khalid Amanali Mohamedali
Lawrence H Cheung
Original Assignee
Res Found Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49447827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3456734(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Res Found Dev filed Critical Res Found Dev
Application granted granted Critical
Publication of DK3456734T3 publication Critical patent/DK3456734T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
DK18202465.3T 2012-10-04 2013-10-04 Serinproteasemolekyler og behandlinger DK3456734T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261709763P 2012-10-04 2012-10-04
US201361762173P 2013-02-07 2013-02-07
US201361762216P 2013-02-07 2013-02-07
EP13779684.3A EP2904004B1 (en) 2012-10-04 2013-10-04 Serine protease molecules and therapies

Publications (1)

Publication Number Publication Date
DK3456734T3 true DK3456734T3 (da) 2022-04-19

Family

ID=49447827

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18202465.3T DK3456734T3 (da) 2012-10-04 2013-10-04 Serinproteasemolekyler og behandlinger

Country Status (7)

Country Link
US (8) US9096840B2 (da)
EP (3) EP4029937A1 (da)
JP (6) JP6306596B2 (da)
AU (2) AU2013326933B2 (da)
CA (1) CA2885376A1 (da)
DK (1) DK3456734T3 (da)
WO (1) WO2014055836A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4029937A1 (en) 2012-10-04 2022-07-20 Research Development Foundation Serine protease molecules and therapies
US9724378B2 (en) * 2014-05-19 2017-08-08 Samsung Electronics Co., Ltd. Fusion protein comprising granzyme B and use thereof
GB2530479A (en) * 2014-08-06 2016-03-30 Hilmar Meek Warenius Peptides useful for treating cancer
CA2971186A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3851523A1 (en) 2015-03-11 2021-07-21 Board Of Regents, The University Of Texas System Transposase polypeptides and uses thereof
RU2753695C2 (ru) 2015-11-04 2021-08-19 Сол Дж. ПРАЙСМЕН Химерные рецепторы антигена, нацеленные на her2
GB201602409D0 (en) * 2016-02-10 2016-03-23 Warenius Hilmar M Compositions and uses thereof
WO2017143026A1 (en) 2016-02-16 2017-08-24 Research Development Foundation Sortase-modified molecules and uses thereof
CA3023491A1 (en) * 2016-06-02 2017-12-07 Riken Adjuvant composition and use thereof
CN109312367B (zh) * 2016-06-06 2023-04-11 艾斯克立必恩股份有限公司 用于药物递送的抗体融合蛋白
CN109963590B (zh) 2016-09-02 2024-03-15 加利福尼亚大学董事会 涉及白介素-6受体α结合单链可变片段的方法和组合物
CN106554422A (zh) * 2016-10-26 2017-04-05 天津科技大学 高透皮吸收皮下靶向释放型因子及构建方法和应用
AU2018347521A1 (en) * 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein
WO2019126960A1 (zh) * 2017-12-25 2019-07-04 清华大学 一种具有蛋白酶活性的多肽及其应用
CN112041333B (zh) * 2018-04-26 2024-06-28 古德T细胞有限公司 新型融合蛋白和用于预防或治疗癌症的包含该融合蛋白的药物组合物
KR20200062462A (ko) * 2018-11-26 2020-06-04 삼성디스플레이 주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
WO2021241719A1 (ja) * 2020-05-28 2021-12-02 中外製薬株式会社 改良されたグランザイムｂ改変体

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
CA2115049C (en) 1991-09-06 2003-10-21 Michael G. Rosenblum Dna sequences encoding gelonin polypeptide
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
IL116559A (en) 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
DK1414471T3 (da) 2001-07-17 2012-07-16 Res Dev Foundation Terapeutiske midler omfattende pro-apoptotiske proteiner
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2003243436A1 (en) 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
US20040146938A1 (en) * 2002-10-02 2004-07-29 Jack Nguyen Methods of generating and screening for proteases with altered specificity
WO2004094478A2 (en) * 2003-04-23 2004-11-04 Borean Pharma A/S Cleavage of fusion proteins using granzyme b protease
US7601341B2 (en) 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
EP1633304A2 (en) 2003-06-05 2006-03-15 Research Development Foundation Vascular endothelial growth factor fusion constructs and uses thereof
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP1824796A4 (en) 2004-11-16 2010-02-17 Avidia Res Inst PROTEIN SKELETONS AND USES THEREOF
EP1814988A2 (en) 2004-11-26 2007-08-08 Pieris AG Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
CN101203247A (zh) * 2005-01-10 2008-06-18 研究发展基金会 用于癌症治疗的靶向嵌合分子
DE102005061886A1 (de) 2005-12-23 2007-07-05 Robert Bosch Gmbh Hochdruckpumpe, insbesondere für eine Kraftstoffeinspritzeinrichtung einer Brennkraftmaschine
JP5167155B2 (ja) 2006-03-09 2013-03-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
EP2257624B9 (en) 2008-02-05 2012-08-01 Medical Research Council Methods and compositions
CN101684159B (zh) * 2008-09-27 2013-04-24 中国医学科学院基础医学研究所 人颗粒酶b蛋白衍生物及其在靶向治疗腺癌中的用途
US8450278B2 (en) 2008-10-15 2013-05-28 Board Of Regents, The University Of Texas System MUC18 targeting peptides
EP4303236A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9528101B2 (en) 2011-09-23 2016-12-27 PHARMED ARTIS GmbH Granzyme B protease variants
EP4029937A1 (en) 2012-10-04 2022-07-20 Research Development Foundation Serine protease molecules and therapies

Also Published As

Publication number Publication date
US20230203467A1 (en) 2023-06-29
CA2885376A1 (en) 2014-04-10
US10920211B2 (en) 2021-02-16
JP7403521B2 (ja) 2023-12-22
EP2904004A2 (en) 2015-08-12
US20200010821A1 (en) 2020-01-09
JP2017140051A (ja) 2017-08-17
EP3456734B1 (en) 2022-01-05
JP6722134B2 (ja) 2020-07-15
JP2019214628A (ja) 2019-12-19
EP3456734A1 (en) 2019-03-20
US20140314760A1 (en) 2014-10-23
US20200308565A1 (en) 2020-10-01
JP2015532102A (ja) 2015-11-09
JP2017205128A (ja) 2017-11-24
US20150010556A1 (en) 2015-01-08
JP6306596B2 (ja) 2018-04-04
AU2017228534A1 (en) 2017-10-05
WO2014055836A3 (en) 2014-05-30
US20190256837A1 (en) 2019-08-22
US9951325B2 (en) 2018-04-24
AU2013326933A1 (en) 2015-04-02
US9096840B2 (en) 2015-08-04
AU2017228534B2 (en) 2019-07-11
US10738295B2 (en) 2020-08-11
US20140140976A1 (en) 2014-05-22
AU2013326933B2 (en) 2017-10-05
US10323239B2 (en) 2019-06-18
JP2023041829A (ja) 2023-03-24
JP2022033246A (ja) 2022-02-28
EP4029937A1 (en) 2022-07-20
EP2904004B1 (en) 2018-11-21
US9499807B2 (en) 2016-11-22
US20180201918A1 (en) 2018-07-19
WO2014055836A2 (en) 2014-04-10
US11535838B2 (en) 2022-12-27

Similar Documents

Publication Publication Date Title
DK3456734T3 (da) Serinproteasemolekyler og behandlinger
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
DK3115372T3 (da) Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf
BR112015000394A2 (pt) aparelho e processo
DK2928533T3 (da) Medicinske slanger og fremgangsmåder til fremstilling
DK2850202T3 (da) Fremgangsmåder og grupper
BR112014028870A2 (pt) solução e processo
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK2904101T3 (da) Intein-modificerede proteaser, fremstilling deraf og industrielle anvendelser
DK3346008T3 (da) Rekombinante mikroorganismer og anvendelser deraf
DK3597644T3 (da) Kationiske aminlipider og anvendelser deraf
DK3027742T3 (da) Enzymvarianter
DK3372239T3 (da) Manipuleret botulinumneurotoksin
DK2920167T3 (da) Hydrazinyl-indol-forbindelser og konjugater
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
BR112014031436A2 (pt) comparar e substituir entrada de tabela dat
DK3197164T3 (da) Afkodningsanordning og afkodningsfremgangsmåde
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
BR112013017172A2 (pt) variantes de plasminogênio e plasmina
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
DK3232663T3 (da) Fremgangsmåder og anordninger til afkodning
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
DK2807160T3 (da) Antifibrotiske forbindelser og anvendelser deraf